DGAP-News: Balda grows with its US subsidiaries in FY 2013 / 2014 and plans operating turnaround during current financial year


DGAP-News: Balda AG / Key word(s): Final Results

Balda grows with its US subsidiaries in FY 2013 / 2014 and plans

operating turnaround during current financial year

30.09.2014 / 19:42


– Preliminary FY 2013 / 2014 results confirmed: sales revenue EUR 70.5

million, EBITDA EUR 4.0 million

– Consolidated net income EUR 5.9 million

– Outlook: sales revenue between EUR 73.0 million and EUR 78.0 million

and positive EBIT

Bad Oeynhausen, 30 September 2014 – Balda AG grew its revenue by 17.7 % to

reach EUR 70.5 million in the 2013 / 2014 financial year (previous year:

EUR 59.9 million). This revenue growth is mainly attributable to the

full-year consolidation for the first-time of the US companies.

Consolidated earnings before interest, tax, depreciation and amortization

(EBITDA) and before extraordinary items rose from EUR 1.8 million to EUR

4.0 million, with the EBITDA margin increasing accordingly from 3.0 % to

5.7 %. The preliminary figures that werepublished at the end of August have

thereby been confirmed.

“Our past financial year was entirely one of consolidation and

transformation. We have also addressed legacy burdens from our history as

far we can, which enables us to now refocus on the expansion of our

operating business and on our strategic further development. This opens up

new prospects for Balda AG to extend its value creation,” as Oliver

Oechsle, Management Board member of Balda AG commented.

Key financials in overview

In the year under review, the cost of materials increased from EUR 23.8

million to EUR 26.9 million in absolute terms due to the twelve-month

inclusion of the US subsidiaries. The cost of materials ratio reduced from

41.8 % to 38.0 % due to the less materials-intensive injection molding

business of the US sites, and a lower level of materials utilized by Balda

Medical GmbH & Co. KG.

Staff costs rose to EUR 29.3 million, compared with EUR 21.2 million in the

previous year. This increase is also primarily attributable to the

consolidation of the US subsidiaries. The staff cost ratio rose from 37.2 %

to 41.3 %.

Depreciation, amortization and impairment losses fell to EUR 6.7 million,

compared with EUR 15.2 million in the prior-year period,when this item was

strongly impacted by goodwill impairment losses at the US subsidiaries.

Other operating expenses of EUR 16.8 million were above the previous year’s

level. When adjusted to reflect extraordinary items, other operating

expenses were up from EUR 13.3 million in the previous year to EUR 15.2

million in the year under review. The smaller proportional increase in

adjusted expenses (around 14 %) compared with the sales revenue growth

(approximately 18 %) reflects the improved Group structures.

After taking into account depreciation, amortization and extraordinary

items, the company reported a result before interest and taxes (EBIT) of

EUR -4.7 million, compared with EUR -12.6 million in the previous-year

period. Net interest income fell by EUR 0.7 million to EUR 1.6 million due

to the continued phase of low interest rates, and a reduction in the cash

position due to dividend payments.

Earnings before taxes (EBT) of EUR 5.3 million were significantly below the

previous year’s EUR 18.7 million, which included the proceeds from the sale

of the remaining TPK shares.

Balda AG reports consolidated net income of EUR 5.9 million for the full

2013 / 2014 financial year, compared with EUR 13.5 million in the

previous-year period. Earnings per share reduced to EUR 0.10 accordingly

(previous year: EUR 0.23).

Consolidated total assets fell by EUR 96.3 million to EUR 263.3 million 30

June 2014. Equity reported a decline to EUR 241.8 million, compared with

EUR 334.5 million in the prior-year period, mainly due to the dividend

payments that were rendered. The equity ratio was down from 93.0 % to 91.8


“We achieved our planning target with our operating growth during the past

financial year. Management also focused on improving our processes and on

streamlining our structures. Balda is significantly stronger as a result,

and at the bottom line, still stands on a robust financial basis due to its

strong equity ratio of 91.8 % – which establishes a starting point for

further growth,” explains Dr. Dieter Brenken, CFO of Balda AG.


Given the efficiency enhancement programs that have been launched and have

already been implemented, as well as a greater level of cost awareness, the

Management Board expects a positive operating result in the 2014 / 2015

financial year. To the extent that macroeconomic conditions do not worsen

significantly and no currently unenvisaged events occur, the Management

Board of Balda AG expects sales revenue of between EUR 73.0 million and EUR

78.0 million for the current financial year (on the basis of the current

Group portfolio), and consequently also a positive EBIT margin in the low

single digit percentage range.

Note to editors:

The 2013 / 2014 annual financial report is available immediately for

downloading from the company’s website at www.balda-group.com; the complete

2013 / 2014 annual report for the Balda Group can be downloaded from the

Balda website from 10 October 2014.


Michael Pfister

Deekeling Arndt Advisors

Phone: +49 (0) 5734 922 2555

Mobile: +49 (0) 160 90560506

Mail: michael.pfister@deekeling-arndt.de

About Balda

Balda (ISIN: DE0005215107) is a provider of first-class solutions in

plastics for demanding, high-quality applications in the fields of

healthcare, lifestyle, automotive and consumer electronics industries.

Balda has operating divisions in Europe and America and maintains

state-of-the-art production facilities at its headquarter in Bad

Oeynhausen, Germany as well as in the USA. The success of Balda, which

employs around 780 people, is based on the deployment of leading-edge,

cost-effective technologies, coupled with the trust-based and close

collaboration with customers.


Balda Group: overview of key figures

(as per IFRS)

In EUR million 01.07.2013 – 01.07.2012 –

30.06.2014 30.06.2013

Sales revenue 70.5 59.9

of which Europe 31.8 36.0

of which America 38.7 23.9

Total operating revenue 70.9 57.1

EBITDA before extraordinary 4.0 1.8


EBITDA after extraordinary items 1.9 2.6

of which Europe -0.7 -0.2

of which America 2.8 3.3

of which Other -0.2 -0.2

EBITDA margin in % (before 5.7 3.0

extraordinary items)

EBIT -4.7 -12.6

Net fixed income 10.0 31.3

Earnings before taxes (EBT) 5.3 18.7

Consolidated net income 5.9 13.5

Earnings per share in euros 0.10 0.23

Key balance sheet figures 30.06.2014 30.06.2014

Total assets 263.3 359.7

Equity 241.8 334.5

Equity ratio in % 91.8 93.0

Number of employees on balance 786 856

sheet date (continuing



30.09.2014 Dissemination of a Corporate News, transmitted by DGAP – a

service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,

Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de


Language: English

Company: Balda AG

Bergkirchener Str. 228

32549 Bad Oeynhausen


Phone: +49 (0) 57 34 / 9 22-0

Fax: +49 (0) 57 34 / 9 22-2604

E-mail: info@Balda.de

Internet: www.balda.de

ISIN: DE0005215107

WKN: 521510

Listed: Regulierter Markt in Frankfurt (Prime Standard);

Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,

München, Stuttgart

End of News DGAP News-Service


289676 30.09.2014